Overview Dividends

(DOC) Healthpeak Properties - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US42250P1030

Properties, Care, Facilities, Research, Outpatient

Health Care REITs
Market Cap in USD: 11,550m
IPO / Inception: 1987-11-05
Return 12m vs S&P 500: -26.8%

EPS (Earnings per Share)

EPS (Earnings per Share) of DOC over the last years for every Quarter: "2020-12": 0.1, "2021-03": 0.08, "2021-06": 0.08, "2021-09": 0.1, "2021-12": 0.12, "2022-03": 0.06, "2022-06": 0.07, "2022-09": 0.28, "2022-12": 0.05, "2023-03": 0.04, "2023-06": 0.05, "2023-09": 0.05, "2023-12": 0.05, "2024-03": 0.01, "2024-06": 0.21, "2024-09": 0.05, "2024-12": 0.05, "2025-03": 0.06, "2025-06": 0.06, "2025-09": -0.1819,
EPS CAGR: -65.80%
EPS Trend: -44.0%
Last SUE: -4.00
Qual. Beats: 0

Revenue

Revenue of DOC over the last years for every Quarter: 2020-12: -126.454, 2021-03: 455.276, 2021-06: 476.238, 2021-09: 481.465, 2021-12: 483.205, 2022-03: 498.372, 2022-06: 517.932, 2022-09: 520.406, 2022-12: 524.468, 2023-03: 525.678, 2023-06: 545.43, 2023-09: 556.243, 2023-12: 553.652, 2024-03: 606.56, 2024-06: 695.504, 2024-09: 700.397, 2024-12: 697.988, 2025-03: 702.889, 2025-06: 694.348, 2025-09: 705.873,
Rev. CAGR: 10.63%
Rev. Trend: 95.2%
Last SUE: 2.35
Qual. Beats: 1

Dividends

Dividend Yield 7.65%
Yield on Cost 5y 6.08%
Yield CAGR 5y -12.14%
Payout Consistency 94.0%
Payout Ratio 504.2%
Risk via 5d forecast
Volatility 25.9%
Value at Risk 5%th 40.7%
Relative Tail Risk -4.23%
Reward TTM
Sharpe Ratio -0.71
Alpha -27.35
CAGR/Max DD -0.17
Character TTM
Hurst Exponent 0.432
Beta 0.502
Beta Downside 0.696
Drawdowns 3y
Max DD 40.71%
Mean DD 20.27%
Median DD 21.58%

Description: DOC Healthpeak Properties October 31, 2025

Healthpeak Properties, Inc. (NYSE: DOC) is a fully integrated REIT and S&P 500 constituent that owns, operates, and develops premium real-estate assets dedicated to healthcare discovery and delivery. Its portfolio is concentrated in life-science labs, medical office buildings, and senior housing, positioning the company within the GICS sub-industry “Health Care REITs.”

Key quantitative highlights (as of the latest FY 2024 filing) include an occupancy rate of roughly 96 % across its life-science and medical-office assets, a FY 2024 adjusted FFO of about $1.12 billion (≈ 6.5 % year-over-year growth), and a dividend yield near 5.8 % paid quarterly. The REIT’s performance is closely tied to macro drivers such as the aging U.S. population (projected to reach 21 % of the total by 2030), sustained federal funding for medical research, and the prevailing interest-rate environment, which influences both borrowing costs and the relative attractiveness of dividend-yielding REITs versus fixed-income alternatives.

If you want a deeper, data-rich analysis of DOC’s valuation metrics and scenario modeling, a quick look at ValueRay’s platform can provide the granular tools needed for further research.

Piotroski VR‑10 (Strict, 0-10) 3.0

Net Income (-38.1m TTM) > 0 and > 6% of Revenue (6% = 168.1m TTM)
FCFTA 0.06 (>2.0%) and ΔFCFTA 1.14pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue -5.18% (prev -26.16%; Δ 20.98pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.06 (>3.0%) and CFO 1.25b > Net Income -38.1m (YES >=105%, WARN >=100%)
Net Debt (9.34b) to EBITDA (1.52b) ratio: 6.14 <= 3.0 (WARN <= 3.5)
Current Ratio 0.87 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (696.4m) change vs 12m ago -0.54% (target <= -2.0% for YES)
Gross Margin 60.08% (prev 60.01%; Δ 0.07pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 14.16% (prev 12.80%; Δ 1.36pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 1.53 (EBITDA TTM 1.52b / Interest Expense TTM 295.0m) >= 6 (WARN >= 3)

Altman Z'' -1.35

(A) -0.01 = (Total Current Assets 981.7m - Total Current Liabilities 1.13b) / Total Assets 19.58b
(B) -0.30 = Retained Earnings (Balance) -5.85b / Total Assets 19.58b
(C) 0.02 = EBIT TTM 451.0m / Avg Total Assets 19.78b
(D) -0.46 = Book Value of Equity -5.17b / Total Liabilities 11.32b
Total Rating: -1.35 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 59.99

1. Piotroski 3.0pt
2. FCF Yield 5.85%
3. FCF Margin 43.60%
4. Debt/Equity 1.24
5. Debt/Ebitda 6.14
6. ROIC - WACC (= -2.06)%
7. RoE -0.47%
8. Rev. Trend 95.18%
9. EPS Trend -43.99%

What is the price of DOC shares?

As of December 22, 2025, the stock is trading at USD 15.99 with a total of 6,535,064 shares traded.
Over the past week, the price has changed by -3.42%, over one month by -9.81%, over three months by -12.03% and over the past year by -15.26%.

Is DOC a buy, sell or hold?

Healthpeak Properties has received a consensus analysts rating of 4.25. Therefore, it is recommended to buy DOC.
  • Strong Buy: 10
  • Buy: 5
  • Hold: 5
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the DOC price?

Issuer Target Up/Down from current
Wallstreet Target Price 20.9 30.5%
Analysts Target Price 20.9 30.5%
ValueRay Target Price 16.3 1.7%

DOC Fundamental Data Overview December 16, 2025

Market Cap USD = 11.55b (11.55b USD * 1.0 USD.USD)
P/E Forward = 66.6667
P/S = 4.1234
P/B = 1.5203
P/EG = 4.0809
Beta = 1.095
Revenue TTM = 2.80b USD
EBIT TTM = 451.0m USD
EBITDA TTM = 1.52b USD
Long Term Debt = 8.76b USD (from longTermDebt, last quarter)
Short Term Debt = 368.1m USD (from shortTermDebt, last quarter)
Debt = 9.43b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 9.34b USD (from netDebt column, last quarter)
Enterprise Value = 20.89b USD (11.55b + Debt 9.43b - CCE 91.0m)
Interest Coverage Ratio = 1.53 (Ebit TTM 451.0m / Interest Expense TTM 295.0m)
FCF Yield = 5.85% (FCF TTM 1.22b / Enterprise Value 20.89b)
FCF Margin = 43.60% (FCF TTM 1.22b / Revenue TTM 2.80b)
Net Margin = -1.36% (Net Income TTM -38.1m / Revenue TTM 2.80b)
Gross Margin = 60.08% ((Revenue TTM 2.80b - Cost of Revenue TTM 1.12b) / Revenue TTM)
Gross Margin QoQ = 58.64% (prev 60.22%)
Tobins Q-Ratio = 1.07 (Enterprise Value 20.89b / Total Assets 19.58b)
Interest Expense / Debt = 0.81% (Interest Expense 76.8m / Debt 9.43b)
Taxrate = 1.09% (-1.21m / -111.1m)
NOPAT = 446.1m (EBIT 451.0m * (1 - 1.09%))
Current Ratio = 0.87 (Total Current Assets 981.7m / Total Current Liabilities 1.13b)
Debt / Equity = 1.24 (Debt 9.43b / totalStockholderEquity, last quarter 7.60b)
Debt / EBITDA = 6.14 (Net Debt 9.34b / EBITDA 1.52b)
Debt / FCF = 7.65 (Net Debt 9.34b / FCF TTM 1.22b)
Total Stockholder Equity = 8.03b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.19% (Net Income -38.1m / Total Assets 19.58b)
RoE = -0.47% (Net Income TTM -38.1m / Total Stockholder Equity 8.03b)
RoCE = 2.69% (EBIT 451.0m / Capital Employed (Equity 8.03b + L.T.Debt 8.76b))
RoIC = 2.63% (NOPAT 446.1m / Invested Capital 16.97b)
WACC = 4.69% (E(11.55b)/V(20.98b) * Re(7.86%) + D(9.43b)/V(20.98b) * Rd(0.81%) * (1-Tc(0.01)))
Discount Rate = 7.86% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 33.33 | Cagr: 12.79%
[DCF Debug] Terminal Value 79.74% ; FCFE base≈1.14b ; Y1≈1.27b ; Y5≈1.66b
Fair Price DCF = 41.39 (DCF Value 28.76b / Shares Outstanding 694.9m; 5y FCF grow 12.72% → 3.0% )
EPS Correlation: -43.99 | EPS CAGR: -65.80% | SUE: -4.0 | # QB: 0
Revenue Correlation: 95.18 | Revenue CAGR: 10.63% | SUE: 2.35 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.09 | Chg30d=+0.019 | Revisions Net=+1 | Analysts=4
EPS next Year (2026-12-31): EPS=0.25 | Chg30d=+0.000 | Revisions Net=-1 | Growth EPS=+2600.0% | Growth Revenue=+1.8%

Additional Sources for DOC Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle